Edwards Lifesciences did not expect to show much revenue growth in the first quarter 2021, but its total sales grew 5% year-over-year during the quarter, including 4% growth for its flagship Sapien transcatheter aortic valve replacement (TAVR) business.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?